7 min read
Key takeaways
- Healthcare organizations face system-wide cash flow variability as policy, pricing, transparency and rate dynamics affect working capital access
- Reliable access to working capital helps reduce reliance on higher-cost borrowing, sustain investment in patient care and operational resiliency, and support transformation initiatives
- Monetizing government and commercial accounts receivable (AR) can provide immediate liquidity; supply chain finance (SCF) delivers early payment on approved payables to stabilize supplier cash cycles
Executive summary
Rising rates, coverage shifts, drug pricing reforms, transparency requirements, 340B program changes, and ongoing cost inflation are likely to impact payment variability and extend cash conversion cycles for healthcare organizations.1 Monetizing government and commercial accounts receivable (AR) can provide immediate liquidity, while supply chain finance (SCF) offers early payment on approved payables. These tactics can help manage working capital variability, reduce reliance on higher-cost borrowing, and support continued investment in patient care, digital modernization and operational resilience.
Navigating regulatory and pricing changes
Healthcare organizations are experiencing a multi‑year transformation that is reshaping cash flow movement. Policy‑driven pricing and transparency changes—including Medicare drug price negotiations and inflationary rebates under the Inflation Reduction Act (IRA), 340B program dynamics and pharmacy benefit manager (PBM) reforms—may influence net price realization and settlement patterns.1,2,3
Simultaneously, policy-driven changes to Medicaid and Affordable Care Act funding and lower Centers for Medicare & Medicaid Services reimbursement rates for Medicare Advantage may contribute to variability in reimbursement levels and add complexity in forecasting net realized revenue.4 Added to this are cost‑of‑goods and capital headwinds as supply chain disruptions and inflation increase input and inventory costs while higher interest rates raise capital costs.5
These factors make forecasting and liquidity planning more complex, resulting in:
-
Increased variability in payment amounts and timing across claims, rebates, chargebacks and other settlements
-
Larger AR balances and higher inventory days
-
Longer, less predictable cash conversion cycles and a greater need for liquidity buffers
As traditional financing becomes more expensive, organizations are seeking to invest in care delivery, digital modernization, cybersecurity and AI‑enabled productivity. Limited liquidity can delay or dilute these investments, highlighting the importance of reliable working capital access.
The following sections explore how these pressures impact each segment and outline working capital solutions that can help organizations strengthen cash flow while investing in patient care and operational resilience.
Healthcare providers: Managing coverage shifts and rising costs
Hospitals, health systems, clinics and physician practices face shifting reimbursement dynamics as insurers and policymakers adjust coverage and reimbursement rules.6 Patient‑pay balances are difficult to collect at point of service, creating sizable AR. Documentation requirements, denials and appeals can delay cash inflows while elevated costs and supply chain uncertainty may require higher inventory levels to protect continuity of care.
Key working capital implications include:
- Maintaining adequate days cash on hand (DCOH) to buffer liquidity during reimbursement delays and cost fluctuations
- Higher AR balances and longer days sales outstanding (DSO)
- More patient responsibility and self‑pay, increasing collection risk and cash‑flow variability
- Additional inventory days to maintain supply resilience, tying up more cash on the balance sheet
- Longer, less predictable cash conversion cycles requiring stronger liquidity buffers to sustain operations and investment
Payers: Balancing lower enrollment and rising costs
Health insurers and health plans collect premiums up front and maintain reserves for future claims. Coverage churn and lower enrollment reduce premium inflows, while rising medical and pharmacy costs might make claim expenses more unpredictable and volatile.7 Transparency and pricing reforms drive more frequent reconciliations.
Payer cash flow challenges include:
-
Timing mismatches between premium inflows and variable claim payments, requiring larger liquidity buffers
-
Margin pressure as enrollment declines and costs rise, increasing the need for cash discipline7
-
More frequent adjustments and settlements, adding forecasting complexity and tightening cash conversion cycles
-
Revenue pressure from enrollment declines may be partially offset as members move to other coverage. However, with costs rising and reimbursement dynamics evolving, payers may (or could) benefit from deploying working capital solutions to sustain reinvestment capacity without increasing reliance on higher‑cost borrowing.
Pharmacy value chain: Responding to market-driven cash flow changes
Drug pricing reforms and market pressures are increasing cash flow variability across the pharmacy value chain. Heightened transparency expectations, ongoing 340B program uncertainty and Medicare drug price negotiations under the IRA are changing net price realization and settlement patterns.11 Meanwhile, PBM transparency and spread pricing reforms are expected to compress margins, Medicaid redeterminations are shifting mix and reimbursement for plans and pharmacies, and supply chain disruptions and inflation are raising costs. Higher interest rates are making working capital tighter as payment variability increases.12,13,14
These pressures affect participants differently:
- Pharmacies experience reimbursement variability and margin pressure as mix shifts and transparency requirements may alter cash inflows and timing15,16,17,18
- Group purchasing organizations (GPOs) navigate contracting changes and price transparency that can affect the timing and level of administrative fees and pass‑throughs*
- PBMs adapt to transparency and spread pricing reforms that alter revenue models and increase compliance and reconciliation activity19
- Players are moving from a Just‑in‑Time to Just‑in‑Case model, while selectively holding inventory of critical components where shortages could significantly impact entire product lines20
*While specific GPO data is limited, these trends mirror documented changes in pharmacy benefit manager (PBM) practices, where regulatory pressure has driven a shift from rebate-based to fee-based revenue models, with PBMs now passing through 95%+ of rebates and relying on transparent administrative fees.
Managing regulatory-induced variability with working capital solutions
In a payment variability environment, liquidity tools delivered through off‑balance‑sheet solutions can help fund growth, maintain financial resilience and limit reliance on higher‑cost borrowing.
-
Receivables finance (Government and Commercial): Monetize outstanding, validated AR for immediate, on‑balance‑sheet liquidity, and align funding to settlement patterns to smooth working capital needs and reduce exposure to payment timing changes. Government receivables finance can bridge gaps from administrative bottlenecks and regulatory changes, helping mitigate delays and maintain liquidity predictability.
-
Supply chain finance: Provide early payment on approved payables to suppliers at buyer linked rates. Shorten supplier cash cycles, support supply assurance and enhance visibility and predictability across the value chain.
These solutions can turn payment variability into reliable liquidity, enabling reinvestment in patient care, digital transformation and operational resilience. And they complement operational process improvements like streamlining disputes and enhancing data analytics.
Case study: Receivables finance strengthens supply chain resilience
Challenge
A U.S. healthcare organization faced tightening liquidity despite strong growth, driven by reimbursement variability, evolving pharmaceutical pricing and transparency reforms, and supply chain cost pressures. Higher interest rates made traditional debt less attractive, risking delays in critical investments in cybersecurity and AI as AR and settlement timing became less predictable.
Objectives
- Stabilize cash flow across providers, payers and the pharmacy value chain without adding higher‑cost debt
- Inject working capital tied to validated receivables to bridge settlement variability
- Support ongoing technology investment in cybersecurity and AI without increasing balance sheet stress
Solution
J.P. Morgan structured a receivables program aligned to the organization’s cash cadence, helping convert validated government, commercial and rebate receivables into on balance sheet liquidity. The company also implemented a complementary SCF program to improve days payable outstanding and offer early payment on approved payables to key suppliers, shortening supplier cash cycles and supporting inventory stability.
Outcome for the organization
- Smoothed period‑end cash volatility and improved predictability of working capital access
- Reduced reliance on higher‑cost borrowing while maintaining reserve discipline
- Accelerated funding for cybersecurity and AI initiatives that reduced administrative burden
- Shortened cash conversion cycles for the organization through AR and for key suppliers through SCF
Preparing for growth in the new era of healthcare
Healthcare organizations that adopt pragmatic working capital solutions can position themselves for growth despite ongoing policy and cost pressures. By monetizing accounts receivable and optimizing working capital across supply chains, they can secure dependable access to cash, reduce days sales outstanding, improve days payable outstanding and smooth cash conversion cycles.
To learn more, visit J.P. Morgan Trade and Working Capital Solutions
J.P. Morgan, JPMorganChase, Chase, Chase Merchant Services, and Chase Payment Solutions are marketing names for certain businesses of JPMorganChase and its subsidiaries worldwide (collectively, “JPMorganChase”). Products or services may be marketed and/or provided by commercial banks such as JPMorgan Chase Bank, N.A., securities or other non-banking affiliates or other JPMorganChase entities. JPMorganChase contact persons may be employees or officers of any of the foregoing entities and the terms “J.P. Morgan”, “JPMorganChase”, “Chase”, “Chase Merchant Services” and “Chase Payment Solutions” if and as used herein include as applicable all such employees or officers and/or entities irrespective of marketing name(s) used. Nothing in this material is a solicitation by JPMorganChase of any product or service which would be unlawful under applicable laws or regulations.
In preparing this material, we have relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources or which was provided to us or which was otherwise reviewed by us. This material is for discussion purposes only and is incomplete without reference to any other applicable briefings provided by JPMorganChase. Neither this material nor any of its contents may be disclosed or used for any other purpose without the prior written consent of JPMorganChase.
This material is not intended to provide legal, tax, investment, accounting, financial, business, real estate, technology or other advice, and should not be used for or relied upon for these purposes. The views, opinions, estimates and strategies expressed in this material are those of the respective individual contributors, authors or speakers, and may differ from those of JPMorganChase, or its employees and affiliates. Any market and/or economic commentary in this material in no way constitutes JPMorganChase research and should not be treated as such. Further, the views expressed in this content may differ from those contained in JPMorganChase research reports. The content in this material has been obtained from sources deemed to be reliable, but JPMorganChase makes no representation or warranty as to its accuracy or completeness. In no event shall JPMorganChase nor any of its directors, officers, employees or agents be liable for any use of, for any decision made or action taken in reliance upon, or for any inaccuracies or errors in or omissions from, this material.
The information in this document may be based upon management forecasts supplied to us and reflects prevailing conditions and our views as of this date, all of which are accordingly subject to change. JPMorganChase’s opinions and estimates constitute J.P. Morgan’s judgment and should be regarded as indicative, preliminary and for illustrative purposes only.
Not all products and services are available in all geographic areas. Eligibility for particular products and services is subject to final determination by JPMorganChase and or its affiliates. This material does not constitute a commitment by any JPMorganChase entity to extend or arrange credit or to provide any other products or services and JPMorganChase reserves the right to withdraw at any time. All products and services are subject to applicable laws, regulations, and applicable approvals and notifications.
Any mentions of third-party trademarks, brand names, products and services are for referential purposes only and any mention thereof is not meant to imply any sponsorship, endorsement, or affiliation.
Notwithstanding anything to the contrary, the statements in this material are not intended to be legally binding. Any products, services, terms or other matters described herein (other than in respect of confidentiality) are subject to, and superseded by, the terms of separate legally binding documentation and/or are subject to change without notice.
JPMorgan Chase Bank, N.A. Member FDIC. Deposits held in non-U.S. branches are not FDIC insured. Non-deposit products are not FDIC insured.
JPMorgan Chase Bank, N.A., organized under the laws of U.S.A. with limited liability.
© 2026 JPMorgan Chase & Co. All Rights Reserved.
